Triptorelin (GnRH) 2mg: Therapeutic Benefits and Premium Quality by Peptides-EU
At Peptides-EU, we offer Triptorelin (GnRH) 2mg of the highest purity, ensuring superior quality and reliability for research and therapeutic applications. This peptide is trusted across Europe for its efficacy in managing hormone-related conditions:
Testosterone Regulation: Triptorelin initially raises testosterone levels by stimulating the pituitary gland. With continued use, it suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to reduced testosterone production. This mechanism is critical in hormone-sensitive therapies.
(Source: National Library of Medicine, Triptorelin Mechanism of Action)Hormone-Responsive Cancer Treatment: Highly effective in managing prostate and breast cancers, it decreases hormones that fuel tumor growth, providing a cornerstone therapy in oncology.
(Source: American Cancer Society, Hormone Therapy for Cancer)Relief for Estrogen-Dependent Conditions: Reduces estrogen production, offering significant symptom relief for conditions like endometriosis and uterine fibroids, enhancing patients' quality of life.
(Source: Journal of Endometriosis and Pelvic Pain Disorders)Precocious Puberty Management: Delays early puberty safely by suppressing premature hormonal activity, allowing normal developmental timelines.
(Source: Endocrine Society Guidelines on Precocious Puberty)Assisted Reproductive Technologies (ART): Plays a key role in IVF protocols, controlling ovarian stimulation and increasing success rates in fertility treatments.
(Source: Human Reproduction Update, GnRH Agonists in ART)
Why Choose Peptides-EU?
- Extreme Purity: Our Triptorelin is manufactured to exceed European standards, ensuring unmatched purity for precise and effective results.
- Trusted Across Europe: Reliable delivery, professional-grade peptides, and adherence to EU regulatory requirements.
Triptorelin by Peptides-EU is the ideal choice for healthcare professionals and researchers seeking high-quality GnRH agonists. Elevate your practice with premium-grade products designed for excellence. Always consult a specialist before use.
Triptorelin, offered at 2mg, is a high-quality specialised research peptide developed for advanced scientific exploration in reproductive endocrinology and oncology. This product is ideal for laboratory settings where precision and reliability are paramount.
- Product Name: Triptorelin 2mg
- Catalogue Number: TRP2-024
- Molecular Formula: C64H82N18O13
- Molecular Weight: 1311.5 g/mol
- Purity: ≥98%
- Form: Lyophilised Solid
Usage and Storage:
Triptorelin is supplied as a lyophilised solid to ensure maximum stability and ease of use in research environments. For best results, follow our website's detailed reconstitution and storage guidelines.
TRIPTORELIN (GnRH) 2mg
Triptorelin (GnRH)
Triptorelin, a decapeptide (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2), is a gonadotropin-releasing hormone agonist (GnRH agonist) used as the acetate or pamoate salts. Triptorelin raises testosterone levels by causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. Triptorelin is marketed under the brand names Decapeptyl (Ipsen) and Diphereline and Gonapeptyl (Ferring Pharmaceuticals). In the United States, it is sold by Watson as Trelstar.In Iran Triptorelin is marketed under the brand name Variopeptyl (Varian Darou Pajooh). In India, Dr. Reddy's Laboratories has launched recently Triptorelin under the brand name "Pamorelin LA". During the treatment of prostate cancer it does cause a surge of testosterone (an initial uplevel of testosterone levels), known as a flare effect. In men a reduction of serum testosterone levels into the range normally seen after surgical castration occurs approximately two to four weeks after initiation of therapy.